Abstract
5090 Background: Advanced Testis Germ Cell Tumors (TGCT) are treated with platinum based chemotherapy. It has been proposed that DNA repair proteins play a role in the TGCT response to cisplatin. DNA repair deficiencies have been related with better treatment response; such deficiencies could be the result of polymorphisms on DNA repair genes or of the presence of High Mobility Group Proteins B (HMGB). Thus we have investigated whether the presence of XPA, ERCC1 and HMGB (mtTFA), as well as the polymorphism C8092A of the ERCC1 gene may influence the survival of TGCT patients treated with cisplatin. Methods: ERCC1, XPA and mtTFA were detected by immunohystochemistry using tissue microarrays in 58 samples from normal and neoplastic tissue. ERCC1 C8092A polymorphism was determined on DNA isolated from blood and paraffin-embedded tumor samples by PCR/RFLP´S. The results were associated with survival and response. Results: Only 58 full filled the inclusion criteria. The age-media was 23 years. According to the...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
